Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Imnovid

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
  • Ota Fuchs
  • Cardiovascular & hematological disorders drug…
  • 2019
  • Corpus ID: 46897258
Thalidomide and its derivatives (lenalidomide, pomalidomide, avadomide, iberdomide hydrochoride, CC-885 and CC-90009) form the… Expand
Is this relevant?
Review
2017
Review
2017
Pomalidomide (Imnovid®; Pomalyst®), an analogue of thalidomide, is an immunomodulatory agent, with several mechanisms of action… Expand
  • table 1
Is this relevant?
Review
2017
Review
2017
The National Institute for Health and Care Excellence (NICE), as part of the institute’s single technology appraisal (STA… Expand
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Is this relevant?
Review
2014
Review
2014
Abstract Multiple myeloma (MM) is a haematological disease characterized by plasma cells proliferation in bone marrow associated… Expand
Is this relevant?
Review
2014
Review
2014
Oral pomalidomide (Imnovid® [EU]; Pomalyst® [USA]) in combination with dexamethasone (in the EU), is approved in several… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
Is this relevant?
2013
2013
Imnovid® ist ein neuer Wirkstoff aus der Klasse der IMiDs® (Immunmodulatoren). Mit einer Standarddosierung von 4 mg (orale Gabe… Expand
Is this relevant?